Innovax
Xiamen, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Chinese vaccine developer employing recombinant protein technology for infectious diseases like HPV and COVID-19.
Infectious Disease
Technology Platform
Proprietary *E. coli*-based recombinant protein system for efficiently producing virus-like particle (VLP) vaccines.
Opportunities
Expansion into international markets and application of its proven platform to new epidemic and pandemic threats.
Risk Factors
Pipeline execution risk and potential pricing pressure from national immunization program procurement.
Competitive Landscape
A leading domestic competitor in the Chinese vaccine market, particularly in HPV, against multinational giants and other local firms.